KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBT (2020 - 2025)

Historic EBT for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.2 million.

  • Recursion Pharmaceuticals' EBT fell 6958.45% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.7 million, marking a year-over-year decrease of 8688.99%. This contributed to the annual value of -$464.8 million for FY2024, which is 3994.24% down from last year.
  • Recursion Pharmaceuticals' EBT amounted to -$162.2 million in Q3 2025, which was down 6958.45% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' EBT's 5-year high stood at -$30.5 million during Q1 2021, with a 5-year trough of -$202.6 million in Q1 2025.
  • In the last 5 years, Recursion Pharmaceuticals' EBT had a median value of -$76.7 million in 2023 and averaged -$92.7 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' EBT crashed by 15393.85% in 2021 and then soared by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' EBT (Quarter) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then crashed by 59.16% to -$97.1 million in 2023, then plummeted by 84.32% to -$178.9 million in 2024, then rose by 9.31% to -$162.2 million in 2025.
  • Its EBT stands at -$162.2 million for Q3 2025, versus -$171.9 million for Q2 2025 and -$202.6 million for Q1 2025.